Other
Peripheral Nerve Injury
7
Pipeline Programs↗
4
Active Trials↗
5
Companies Involved↗
Peripheral Nerve Injury is an early-stage landscape with 7 programs across 5 companies. The most active players are Artgen Biotech, Veloxis Pharmaceuticals, GSK. 2 therapies are approved.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 11
Phase 24
Phase 3
No programs
Analysis
Trial Status
10
clinical trials
Recruiting3 · 30%
Completed3 · 30%
Not yet recruiting1 · 10%
No longer available1 · 10%
Unknown status1 · 10%
Withdrawn1 · 10%
Clinical Trials
Trial Activity
10 trials
Safety and Efficacy of Autologous Human Schwann Cell (ahSC) Augmentation in Severe Peripheral Nerve Injury (PNI)
Recruiting·—·Phase 1·NCT05541250·30 enrolled
Ultrasound Guided Placental Growth Factor Vs Platelet Rich Plasma Injection in Peripheral Nerve Injury: an Interventional Study
Not yet recruiting·—·N/A·NCT06638008·75 enrolled
Topical Lidocaine: Predictors of Response in Peripheral Nerve Injury
Completed·—·Phase 4·NCT01112748·24 enrolled
Emergent Expanded Access for ahSC Augmentation of Nerve Autografts After Severe Peripheral Nerve Injury.
No longer available·—·N/A·NCT02510079
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)